53
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS study

&
Pages 631-639 | Published online: 17 Apr 2014

References

  • BrometEAndradeLHHwangICross-national epidemiology of DSM-IV major depressive episodeBMC Med201199021791035
  • WittchenHUJacobiFRehmJThe size and burden of mental disorders and other disorders of the brain in Europe 2010Eur Neuropsychopharmacol201121965567921896369
  • KesslerRCBerglundPDemierONational Comorbidity Survey ReplicationThe epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)JAMA2003289233095310512813115
  • PalssonSPOstlingSSkoogIThe incidence of first-onset depression in a population followed from the age of 70 to 85Psychol Med20013171159116811681542
  • KruijshaarMEBarendregtJVosTde GraafRSpijkerJAndrewsGLifetime prevalence estimates of major depression: an indirect estimation method and a quantification of recall biasEur J Epidemiol200520110311115756910
  • PattenSBAccumulation of major depressive episodes over time in a prospective study indicates that retrospectively assessed lifetime prevalence estimates are too lowBMC Psychiatry200991919422724
  • AndrewsGPoultonRSkoogILifetime risk of depression: restricted to a minority of waiting for most?Br J Psychiatry200518749549616319399
  • PattenSBWangJLWilliamsJVLavoratoDHBullochAEliasziwMProspective evaluation of the effect of major depression on working status in a population sampleCan J Psychiatry2009541284184520047723
  • LenzeEJSchulzRMartireLMThe course of functional decline in older people with persistently elevated depressive symptoms: longitudinal findings from the Cardiovascular Health StudyJ Am Geriatr Soc200553456957515817000
  • MurrayCJLLopezADAlternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease StudyLancet19973499064149815049167458
  • OlesenJGustavssonASvenssonMWittchenHUJönssonBCDBE2010 study group; European Brain CouncilThe economic cost of brain disorders in EuropeEur J Neurol201219115516222175760
  • de BodinatCGuardiola-LemaitreBMocaërERenardPMuñozCMillanMJAgomelatine, the first melatonergic antidepressant: discovery, characterization and developmentNat Rev Drug Discov20109862864220577266
  • DemyttenaereKAgomelatine: a narrative reviewEur Neuropsychopharmacol201121Suppl 4S703S70921835598
  • Quera-SalvaMAHajakGPhilipPComparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patientsInt Clin Psychopharmacol201126525226221829106
  • KennedySHEmsleyRPlacebo-controlled trial of agomelatine in the treatment of major depressive disorderEur Neuropsychopharmacol20061629310016249073
  • OliéJPKasperSEfficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorderInt J Neuropsychopharmacol200710566167317477888
  • LemoinePGuilleminaultCAlvarezEImprovement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxineJ Clin Psychiatry200768111723173218052566
  • KasperSHajakGWulffKEfficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertralineJ Clin Psychiatry201071210912020193645
  • HaleACorralRMMencacciCRuizJSSeveroCAGentilVSuperior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind studyInt Clin Psychopharmacol201025630531420856123
  • LauxGVIVALDI Study GroupThe antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDIPharmacopsychiatry201245728429122592503
  • SeemüllerFRiedelMObermeierMOutcomes of 1014 naturalistically treated in patients with major depressive episodeEur Neuropsychopharmacol201020534635520097046
  • TrivediMHRushAJNierenbergAASTAR*D Study TeamEvaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practiceAm J Psychiatry20061631284016390886
  • KatzMMBowdenCLFrazerARethinking depression and the actions of antidepressants: uncovering the links between the neural and behavioural elementsJ Affect Disord20101201–3162319735945
  • Machado-VieiraRSalvadoreGLuckenbaughDAManjiHKZarateCAJrRapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorderJ Clin Psychiatry200869694695818435563
  • ChangTFavaMThe future of psychopharmacology of depressionJ Clin Psychiatry201071897197520797377
  • PerlisRHOstacherMJGoldbergJFTransition to mania during treatment of bipolar depressionNeuropsychopharmacology201035132545255220827274
  • GoodwinGMEmsleyRRembrySRouillonFAgomelatine Study GroupAgomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trialJ Clin Psychiatry20097081128113719689920
  • MontgomerySAKennedySHBurrowsGDLejoyeuxMHindmarchIAbsence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation studyInt Clin Psychopharmacol200419527128015289700